Molecular and environmental contributors to neurological complications in sickle cell disease
Sickle cell disease (SCD) is an inherited hemoglobinopathy in which affected hemoglobin polymerizes under hypoxic conditions resulting in red cell distortion and chronic hemolytic anemia. SCD affects millions of people worldwide, primarily in Sub-Saharan Africa and the Indian subcontinent. Due to vaso-occlusion of sickled red cells within the microvasculature, SCD affects virtually every organ system and causes significant morbidity and early mortality. The neurological complications of SCD are particularly devastating and diverse, ranging from overt stroke to covert cerebral injury, including silent cerebral infarctions and blood vessel tortuosity. However, even individuals without evidence of neuroanatomical changes in brain imaging have evidence of cognitive deficits compared to matched healthy controls likely due to chronic cerebral hypoxemia and neuroinflammation. In this review, we first examined the biological contributors to SCD-related neurological complications and then discussed the equally important socioenvironmental contributors. We then discuss the evidence for neuroprotection from the two primary disease-modifying therapies, chronic monthly blood transfusions and hydroxyurea, and end with several experimental therapies designed to specifically target these complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:248 |
|---|---|
| Enthalten in: |
Experimental biology and medicine (Maywood, N.J.) - 248(2023), 15 vom: 09. Aug., Seite 1319-1332 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karkoska, Kristine A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cognitive decline |
|---|
| Anmerkungen: |
Date Completed 06.11.2023 Date Revised 10.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/15353702231187646 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361860129 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361860129 | ||
| 003 | DE-627 | ||
| 005 | 20240310231849.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/15353702231187646 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1322.xml |
| 035 | |a (DE-627)NLM361860129 | ||
| 035 | |a (NLM)37688519 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karkoska, Kristine A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular and environmental contributors to neurological complications in sickle cell disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.11.2023 | ||
| 500 | |a Date Revised 10.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Sickle cell disease (SCD) is an inherited hemoglobinopathy in which affected hemoglobin polymerizes under hypoxic conditions resulting in red cell distortion and chronic hemolytic anemia. SCD affects millions of people worldwide, primarily in Sub-Saharan Africa and the Indian subcontinent. Due to vaso-occlusion of sickled red cells within the microvasculature, SCD affects virtually every organ system and causes significant morbidity and early mortality. The neurological complications of SCD are particularly devastating and diverse, ranging from overt stroke to covert cerebral injury, including silent cerebral infarctions and blood vessel tortuosity. However, even individuals without evidence of neuroanatomical changes in brain imaging have evidence of cognitive deficits compared to matched healthy controls likely due to chronic cerebral hypoxemia and neuroinflammation. In this review, we first examined the biological contributors to SCD-related neurological complications and then discussed the equally important socioenvironmental contributors. We then discuss the evidence for neuroprotection from the two primary disease-modifying therapies, chronic monthly blood transfusions and hydroxyurea, and end with several experimental therapies designed to specifically target these complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Sickle cell disease | |
| 650 | 4 | |a cognitive decline | |
| 650 | 4 | |a hemolytic anemia | |
| 650 | 4 | |a hypoxemia | |
| 650 | 4 | |a neuroinflammation | |
| 650 | 4 | |a vasculopathy | |
| 650 | 7 | |a Hydroxyurea |2 NLM | |
| 650 | 7 | |a X6Q56QN5QC |2 NLM | |
| 700 | 1 | |a Gollamudi, Jahnavi |e verfasserin |4 aut | |
| 700 | 1 | |a Hyacinth, Hyacinth I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental biology and medicine (Maywood, N.J.) |d 2001 |g 248(2023), 15 vom: 09. Aug., Seite 1319-1332 |w (DE-627)NLM112670172 |x 1535-3699 |7 nnns |
| 773 | 1 | 8 | |g volume:248 |g year:2023 |g number:15 |g day:09 |g month:08 |g pages:1319-1332 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/15353702231187646 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 248 |j 2023 |e 15 |b 09 |c 08 |h 1319-1332 | ||